Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis
- 3 March 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 106 (9), 3426-3430
- https://doi.org/10.1073/pnas.0813348106
Abstract
Claudin-3 (CLDN3) is a tight junction protein that is overexpressed in 90% of ovarian tumors. Previous in vitro studies have indicated that CLDN3 overexpression promotes the migration, invasion, and survival of ovarian cancer cells. Here, we investigated the efficacy of lipidoid-formulated CLDN3 siRNA in 3 different ovarian cancer models. Intratumoral injection of lipidoid/CLDN3 siRNA into OVCAR-3 xenografts resulted in dramatic silencing of CLDN3, significant reduction in cell proliferation, reduction in tumor growth, and a significant increase in the number of apoptotic cells. Intraperitoneal injection of lipidoid-formulated CLDN3 siRNA resulted in a substantial reduction in tumor burden in MISIIR/TAg transgenic mice and mice bearing tumors derived from mouse ovarian surface epithelial cells. Ascites development was reduced in CLDN3 siRNA-treated mice, suggesting the treatment effectively suppressed metastasis. Toxicity was not observed after multiple i.p. injections. Importantly, treatment of mice with nonimmunostimulatory 2′-OMe modified CLDN3 siRNA was as effective in suppressing tumor growth as unmodifed siRNA. These results suggest that lipidoid-formulated CLDN3 siRNA has potential as a therapeutic for ovarian cancer.Keywords
This publication has 21 references indexed in Scilit:
- Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancerGynecologic Oncology, 2008
- A combinatorial library of lipid-like materials for delivery of RNAi therapeuticsNature Biotechnology, 2008
- Overcoming the Innate Immune Response to Small Interfering RNAHuman Gene Therapy, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Nanoparticulate delivery of suicide DNA to murine prostate and prostate tumorsThe Prostate, 2007
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Intraperitoneal Chemotherapy Comes of AgeNew England Journal of Medicine, 2006
- Claudin Proteins in Human Cancer: Promising New Targets for Diagnosis and TherapyCancer Research, 2005
- Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cellsGene Therapy, 2005
- Treatment of Chemotherapy-Resistant Human Ovarian Cancer Xenografts in C.B-17/SCID Mice by Intraperitoneal Administration of Clostridium perfringens EnterotoxinCancer Research, 2005